15.91
-0.51(-3.11%)
Currency In USD
Address
215 First Street
Cambridge, MA 02142
United States of America
Phone
617 274 4000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
1372
First IPO Date
June 04, 1997
Name | Title | Pay | Year Born |
Mr. Douglas S. Ingram Esq. | President, Chief Executive Officer & Director | 1.98M | 1963 |
Mr. Joseph Bratica | Controller & Vice President | 438,513 | 1964 |
Mr. Bilal Arif | Executive Vice President & Chief Technical Operations Officer | 921,868 | 1972 |
Mr. Dallan Murray | Executive Vice President & Chief Customer Officer | 1.05M | 1970 |
Dr. Louise R. Rodino-Klapac Ph.D. | Executive Vice President, Chief Scientific Officer and Head of Research & Development | 1.12M | 1978 |
Mr. Ian Michael Estepan | Executive Vice President & Chief Financial Officer | 1.14M | 1976 |
Ms. Cristin L. Rothfuss J.D. | Executive Vice President, Chief General Counsel & Corporate Secretary | 0 | N/A |
Dr. Diane L. Berry Ph.D. | Executive Vice President and Chief of Global Policy & Advocacy Officer | 0 | N/A |
Ms. Francesca T. Nolan | Executive Director of Investor Relations and Corporate Communications | 0 | N/A |
Ms. Alison Nasisi | Executive Vice President & Chief People Officer | 0 | N/A |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.